BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
This Quarter Return
+43.59%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$1.04B
AUM Growth
+$1.04B
(+17%)
Cap. Flow
-$78.9M
Cap. Flow
% of AUM
-7.56%
Top 10 Holdings %
Top 10 Hldgs %
81.6%
Holding
33
New
2
Increased
4
Reduced
3
Closed
6
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$75.1M |
| 2 |
Revolution Medicines
RVMD
|
$31.9M |
| 3 |
Annexon
ANNX
|
$10.7M |
| 4 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$4.87M |
| 5 |
X4 Pharmaceuticals
XFOR
|
$801K |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$71.2M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$37.9M |
| 3 |
Pharvaris
PHVS
|
$24.7M |
| 4 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$22.2M |
| 5 |
Natera
NTRA
|
$18.8M |
Sector Composition
| 1 | Healthcare | 98.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $263M | 25.23% | 3,577,267 | – | – |
|
2
NewAmsterdam Pharma
NAMS
$2.71B
| $117M | 11.21% | 10,473,913 | – | – |
|
|
3
Pharvaris
PHVS
$1.39B
| $110M | 10.5% | 3,904,319 -880,355 | -18% | -$24.7M |
|
4
Disc Medicine
IRON
$2.07B
| $77M | 7.38% | 1,332,545 | – | – |
|
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $75.1M | 7.2% | +324,619 | New | +$75.1M |
|
6
Savara
SVRA
$567M
| $66.9M | 6.41% | 14,232,751 | – | – |
|
7
Cabaletta Bio
CABA
$133M
| $45.4M | 4.35% | 2,000,000 | – | – |
|
|
8
Annexon
ANNX
$226M
| $36.6M | 3.51% | 8,061,719 +2,359,793 | +41% | +$10.7M |
|
|
9
Revolution Medicines
RVMD
$7.1B
| $31.9M | 3.06% | +1,112,396 | New | +$31.9M |
|
10
Tango Therapeutics
TNGX
$747M
| $28.6M | 2.75% | 2,892,663 | – | – |
|
|
11
Natera
NTRA
$23.1B
| $25.1M | 2.4% | 400,197 -300,000 | -43% | -$18.8M |
|
|
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $21.4M | 2.05% | 2,749,808 +625,114 | +29% | +$4.87M |
|
13
Mersana Therapeutics
MRSN
$36.5M
| $20.1M | 1.93% | 8,663,673 | – | – |
|
14
Solid Biosciences
SLDB
$427M
| $19.2M | 1.84% | 3,130,422 | – | – |
|
15
Nurix Therapeutics
NRIX
$714M
| $18.8M | 1.8% | 1,822,883 | – | – |
|
|
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $15.6M | 1.49% | 1,431,058 | – | – |
|
|
17
X4 Pharmaceuticals
XFOR
$84.2M
| $14.2M | 1.36% | 16,915,784 +955,196 | +6% | +$801K |
|
18
Arcutis Biotherapeutics
ARQT
$1.86B
| $9.69M | 0.93% | 3,000,000 | – | – |
|
19
C4 Therapeutics
CCCC
$185M
| $9.28M | 0.89% | 1,642,210 | – | – |
|
20
Invivyd
IVVD
$204M
| $7.63M | 0.73% | 1,937,207 | – | – |
|
21
Atea Pharmaceuticals
AVIR
$267M
| $7.58M | 0.73% | 2,485,638 | – | – |
|
22
Rapid Micro Biosystems
RPID
$107M
| $6.24M | 0.6% | 8,434,560 | – | – |
|
23
Nautilus Biotechnolgy
NAUT
$85.9M
| $5.98M | 0.57% | 2,000,000 | – | – |
|
|
TSVT
24
DELISTED
2seventy bio
TSVT
| $5.69M | 0.55% | 1,331,801 -77,100 | -5% | -$329K |
|
25
Aclaris Therapeutics
ACRS
$209M
| $3.68M | 0.35% | 3,500,000 +100,000 | +3% | +$105K |
|